Get the Stockscreener App
0.30
27.18%
-0.112
Pre-market:
.27
-0.03
-10.00%
Processa Pharmaceuticals Inc stock is traded at $0.30, with a volume of 50.63M.
It is down -27.18% in the last 24 hours and down -45.36% over the past month.
See More
Previous Close:
$0.412
Open:
$0.48
24h Volume:
50.63M
Relative Volume:
52.27
Market Cap:
$2.17M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.0622
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
-23.39%
1M Performance:
-45.36%
6M Performance:
-77.44%
1Y Performance:
-88.19%
1-Day Range:
$0.24
$0.4878
1-Week Range:
$0.24
$0.4878
52-Week Range:
$0.24
$3.305
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
7380 COCA COLA DRIVE, HANOVER
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.30 | 2.17M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Processa Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Friday - Defense World
Processa Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Processa Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Thursday - Defense World
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference - The Manila Times
Cancer Therapy Innovator Processa Pharmaceuticals Opens Door to Investors at Elite MedInvest Conference - StockTitan
Processa Pharmaceuticals stock hits 52-week low at $0.43 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.43 - Investing.com India
Ulcerated Necrobiosis Lipoidica Market to Expand Significantly by 2034, States DelveInsight Reports | Processa Pharmaceuticals - Barchart
Processa Pharmaceuticals stock hits 52-week low at $0.46 - Investing.com
Processa Pharma Stock Price, Quotes and Forecasts - Benzinga
The Insider Secrets to Processa Pharmaceuticals: A Dark Horse in the Race - Elblog.pl
Hidden Gems: Why Insiders Are Banking on Processa Pharmaceuticals - Bit Perfect Solutions
Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Processa Pharmaceuticals faces Nasdaq delisting risk over share price By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (NASDAQ:PCSA) Publishes Investor Presentation - Defense World
Processa Pharmaceuticals faces Nasdaq delisting risk over share price - Investing.com
Processa Pharmaceuticals IncOn Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance - Marketscreener.com
Processa Pharmaceuticals Inc (PCSA) Shares Soar Above 1-Year High - The News Heater
Processa Pharmaceuticals to Present at 2025 BIO CEO & Investor Conference - Nasdaq
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Processa Pharma's Cancer Pipeline Takes Center Stage at Elite BIO Investor Conference - StockTitan
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Financial Analysis: Processa Pharmaceuticals Inc (PCSA)’s Ratios Unveil Key Insights - The Dwinnex
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 - MSN
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Processa Pharmaceuticals Raises $5M in Public Offering - TipRanks
Processa CEO Doubles Down: Purchases Shares at 30% Premium in $5M Strategic Raise - StockTitan
Processa Pharmaceuticals director David Young buys $99,288 in stock - Investing.com India
Processa Pharmaceuticals' chief business officer buys $34,691 in stock - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Processa Pharmaceuticals' chief business officer buys $34,691 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals director David Young buys $99,288 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 By Investing.com - Investing.com UK
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Ulcerated Necrobiosis Lipoidica Market to Reach New Heights - openPR
Processa Pharmaceuticals stock hits 52-week low at $0.65 By Investing.com - Investing.com Canada
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa CEO and Board Members Double Down: Major Insider Buying in Latest $5M Deal - StockTitan
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):